— Funding to be received for the development of a novel therapeutic treatment to engineer corneas to resist graft rejection —
Oxford, UK – 14 August 2013: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: Oxford Biomedica), the leading gene-based biopharmaceutical company, notes that the UK’s innovation agency, the Technology Strategy Board (TSB) has announced that the Company has been selected as one of seven winners of a funding award under the 2013 Supporting Regenerative Medicines and Cell Therapies competition. The funding will be used to fund the development of a novel therapeutic treatment to engineer corneas to resist graft rejection utilising Oxford BioMedica’s proprietary LentiVector® platform technology. The funding award is subject to due diligence and final confirmation by the Technology Strategy Board and further details will be disclosed in due course.
-Ends-